Migraine Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Migraine Drugs Market: By Drug Type, (Prophylactic, (Topiramate, Botulinum toxin), Abortive (Ergot Alkaloids, Triptans), By Route of Administration (Injectables, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), Geography

 

$ PRICE - $ 2,000.00$ 6,900.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

The global migraine drugs market size was valued at USD 2000 million in 2020 and expected to reach USD 2527.40 million by 2028 growing at a CAGR of 3.4% during the forecast period from 2022 to 2028. Migraine Drugs Market is a primary headache disorder characterized by moderate to a severe headache. Typically migraine headaches affect half of the head and generally pulsatile. A migraine may last in a range of two hours to 72 hours. Other symptoms may include nausea, vomiting, sensitivity to light, smell and sound. Migraines may be preceded by an aura of sensory disturbances followed by severing an often onside headache. There are two types of migraine drugs are present in the market. Prophylactic drugs are used for the prevention of precedence of a migraine. Whereas, no particular migraine therapy drugs are available. Global migraine drugs market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, rise in R&D activities by the market players to develop new drugs and expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global market share. However, availability of the generic drugs, other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period. Global migraine drugs market expected to grow at significant rate owing to the prevalence of the migraine worldwide. The market is witnessing acquisitions and mergers of the market players. For instance, in March 2017, Eli Lilly and Company has acquired migraine drugs company, CoLucid Pharmaceuticals for about US $960Mn. Similarly, in June 2017, Grünenthal has entered into agreement to acquire global rights for AstraZeneca’s migraine drug Zomig, outside Japan Market. Furthermore, market has many drugs which are under development for the treatment of a migraine. For instance, Lasmiditan is an investigational drug for the treatment of an acute migraine being developed by Eli Lilly in phase 3 clinical trials.

Migraine Drugs Market

MARKET SUMMARY
-
3.4%CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 3.4%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Migraine Drugs Market

  • The report on global Migraine Drugs Market gives historical, current, and future market sizes (US$ Mn) on the basis of drug type, route of administration, distribution channel and geography.
  • Migraine Drugs Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • AstraZeneca Plc. (U.K.)
  • Allergan Plc. (U.S.)
  • Pfizer, Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline plc (U.K)
Migraine Drugs Market Dynamics

Global migraine drugs market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, rise in R&D activities by the market players to develop new drugs and expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global market share. However, availability of the generic drugs, other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period.


North-America Got Significant Share

Migraine Drugs Market

Geographically migraine drugs market is divided into five key regions, i.e. Europe, North America, Latin America, Asia- Pacific, and The Middle East & Africa. North America migraine drugs market is anticipated to grow at significant rates owing to the factors such as rise in the occurrence of migraine, greater healthcare expenditure, and recent product launches. Asia Pacific market is expected to have notable market growth over the forecast period owing to the growth in a number of people suffering from the migraine and growing awareness related to early diagnosis and treatment. China and India expected to have lucrative growth opportunities owing to the lifestyle changes and high prevalence rates of migraine in the countries

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market and forecast
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Migraine Drugs Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The migraine drugs market is projected to expand at a CAGR of 3.4% during the forecast period

AstraZeneca Plc. (U.K.), Allergan Plc. (U.S.), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline plc (U.K)

North America is the fastest-growing region for the migraine drugs market

 


Report

Table Of Content


Report

Company Profile

Competition Assessment: Global Migraine Drugs Market

Some of the players in global migraine drugs market include

  • AstraZeneca Plc. (U.K.)
  • Allergan Plc. (U.S.)
  • Pfizer, Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline plc (U.K)
  • Eli Lilly & Co. (U.S.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Valeant Pharmaceutical International, Inc. (Canada)
  • Janssen Pharmaceutical Company (Johnson & Johnson) (U.S.)
  • Endo International plc. (U.S.)
  • Zosano Pharma Inc. (U.S.)
  • Alder Biopharmaceuticals (U.S.)

Description

The global migraine drugs market size was valued at USD 2000 million in 2020 and expected to reach USD 2527.40 million by 2028 growing at a CAGR of 3.4% during the forecast period from 2022 to 2028. Migraine Drugs Market is a primary headache disorder characterized by moderate to a severe headache. Typically migraine headaches affect half of the head and generally pulsatile. A migraine may last in a range of two hours to 72 hours. Other symptoms may include nausea, vomiting, sensitivity to light, smell and sound. Migraines may be preceded by an aura of sensory disturbances followed by severing an often onside headache. There are two types of migraine drugs are present in the market. Prophylactic drugs are used for the prevention of precedence of a migraine. Whereas, no particular migraine therapy drugs are available. Global migraine drugs market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, rise in R&D activities by the market players to develop new drugs and expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global market share. However, availability of the generic drugs, other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period. Global migraine drugs market expected to grow at significant rate owing to the prevalence of the migraine worldwide. The market is witnessing acquisitions and mergers of the market players. For instance, in March 2017, Eli Lilly and Company has acquired migraine drugs company, CoLucid Pharmaceuticals for about US $960Mn. Similarly, in June 2017, Grünenthal has entered into agreement to acquire global rights for AstraZeneca’s migraine drug Zomig, outside Japan Market. Furthermore, market has many drugs which are under development for the treatment of a migraine. For instance, Lasmiditan is an investigational drug for the treatment of an acute migraine being developed by Eli Lilly in phase 3 clinical trials.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX